SCHEMBL20070177

SCHEMBL20070177

CN1CCC(Cc2ccccn2)(NC(=O)CC2CNC2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 3/20 0.52
HPGD P15428 2/20 0.43
RECQL P46063 1/20 0.43
ALDH1A1 P00352 2/20 0.38
CYP3A4 P08684 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
KEAP1 Q14145 1/20 0.37
NFE2L2 Q16236 1/20 0.37
CYP46A1 Q9Y6A2 1/20 0.37
TSHR P16473 2/20 0.37
ALOX15 P16050 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
SHMT2 P34897 1/20 0.36
POLB P06746 2/20 0.36
GAA P10253 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KDM4E B2RXH2 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20147912 0.89 RET (0.50) RETHPGDRECQLALDH1A1MEN1
SCHEMBL20158529 0.89 RET (0.50) RETHPGDRECQLALDH1A1CYP3A4
SCHEMBL22857062 0.89 RET (0.50) RETHPGDRECQLALDH1A1MEN1
SCHEMBL21651950 0.83 RET (0.56) RETALDH1A1TSHRALOX15L3MBTL1
SCHEMBL25502420 0.78 RET (0.51) RETALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL20069619 0.77 RET (0.52) RETMEN1KMT2ACYP46A1POLB
SCHEMBL20158570 0.77 RET (0.50) RETALDH1A1CYP46A1TSHRSHMT2
SCHEMBL20205876 0.77 RET (0.57) RETPOLB
SCHEMBL20069634 0.77 RET (0.52) RETALDH1A1MEN1KMT2ATSHR
SCHEMBL20069459 0.76 RET (0.51) RETCYP46A1SHMT2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200383966-A9 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2020-12-10 US disclosed
US-20200030311-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA, INC. 2020-01-30 US disclosed
WO-2018071454-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ANDREWS STEVEN W (US) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200383966-A9 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 RET 1/4885HPGD 3857/4885RECQL 627/4885
US-20200030311-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 RET 1/4885HPGD 3857/4885RECQL 627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.